Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    June 2018
  1. ARAI J, Goto K, Tanoue Y, Ito S, et al
    Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
    Int J Cancer. 2018 Jun 6. doi: 10.1002/ijc.31615.
    PubMed     Text format     Abstract available


    April 2018
  2. LIU Y, De Keyzer F, Wang Y, Wang F, et al
    The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31567.
    PubMed     Text format     Abstract available


  3. CHEN CJ, Yang YH, Lin MH, Lee CP, et al
    Herbal Medicine Containing Aristolochic Acid and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection.
    Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31544.
    PubMed     Text format     Abstract available


    March 2018
  4. LI X, Guo X, Li D, Du X, et al
    Multi-regional Sequencing Reveals Intratumor Heterogeneity and Positive Selection of Somatic mtDNA Mutations in Hepatocellular Carcinoma and Colorectal Cancer.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31395.
    PubMed     Text format     Abstract available


  5. JAQUET A, Tchounga B, Tanon A, Bagny A, et al
    Etiology of hepatocellular carcinoma in West Africa, a case-control study.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31393.
    PubMed     Text format     Abstract available


    February 2018
  6. PULTE D, Weberpals J, Schroder CC, Emrich K, et al
    Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21(st) century.
    Int J Cancer. 2018 Feb 26. doi: 10.1002/ijc.31322.
    PubMed     Text format     Abstract available


    December 2017
  7. CHANG CJ, Yang YH, Chiu CJ, Lu LC, et al
    Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.
    Int J Cancer. 2017 Dec 20. doi: 10.1002/ijc.31216.
    PubMed     Text format     Abstract available


    November 2017
  8. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    PubMed     Text format     Abstract available


    October 2017
  9. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Text format     Abstract available


    September 2017
  10. JIANG W, Shen Y, Ding Y, Ye C, et al
    A naive Bayes algorithm for tissue origin diagnosis (TOD-Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31054.
    PubMed     Text format     Abstract available


  11. WANG W, Xiao X, Chen X, Huo Y, et al
    Tumor-suppressive miR-145 co-repressed by TCF4-beta-catenin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31056.
    PubMed     Text format     Abstract available


  12. SONG IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, et al
    The Contribution of Toll-Like Receptor Signaling to the Development of Liver Fibrosis and Cancer in Hepatocyte-Specific TAK1-Deleted Mice.
    Int J Cancer. 2017 Sep 5. doi: 10.1002/ijc.31029.
    PubMed     Text format     Abstract available


    August 2017
  13. LI S, Dai W, Mo W, Li J, et al
    By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Int J Cancer. 2017 Aug 31. doi: 10.1002/ijc.31022.
    PubMed     Text format     Abstract available


  14. DENG H, Eckel SP, Liu L, Lurmann FW, et al
    Particulate matter air pollution and liver cancer survival.
    Int J Cancer. 2017;141:744-749.
    PubMed     Text format     Abstract available


    July 2017
  15. YANG B, Petrick JL, Kelly SP, Graubard BI, et al
    Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort.
    Int J Cancer. 2017;141:271-278.
    PubMed     Text format     Abstract available


    June 2017
  16. LIN B, Zhu M, Wang W, Li W, et al
    Structural basis for alpha fetoprotein-mediated inhibition of caspase-3 activity in hepatocellular carcinoma cells.
    Int J Cancer. 2017 Jun 27. doi: 10.1002/ijc.30850.
    PubMed     Text format     Abstract available


  17. ZHANG Q, Yuan XF, Lu Y, Li ZZ, et al
    Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
    Int J Cancer. 2017 Jun 23. doi: 10.1002/ijc.30846.
    PubMed     Text format     Abstract available


  18. SHI H, Fang W, Liu M, Fu D, et al
    Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.
    Int J Cancer. 2017 Jun 12. doi: 10.1002/ijc.30831.
    PubMed     Text format     Abstract available


  19. WANG K, Nie X, Rong Z, Fan T, et al
    B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
    Int J Cancer. 2017 Jun 5. doi: 10.1002/ijc.30823.
    PubMed     Text format     Abstract available


  20. NDERITU P, Bosco C, Garmo H, Holmberg L, et al
    The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort.
    Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30818.
    PubMed     Text format     Abstract available


  21. MTEYREK A, Filipski E, Guettier C, Oklejewicz M, et al
    Critical cholangiocarcinogenesis control by cryptochrome clock genes.
    Int J Cancer. 2017;140:2473-2483.
    PubMed     Text format     Abstract available


    May 2017
  22. SHOJI H, Yoshio S, Mano Y, Doi H, et al
    Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Int J Cancer. 2017 May 27. doi: 10.1002/ijc.30804.
    PubMed     Text format     Abstract available


  23. CAI ZX, Chen G, Zeng YY, Dong XQ, et al
    Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
    Int J Cancer. 2017 May 22. doi: 10.1002/ijc.30798.
    PubMed     Text format     Abstract available


  24. CHU YJ, Yang HI, Wu HC, Liu J, et al
    Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30782.
    PubMed     Text format     Abstract available


  25. LEE TY, Wu JC, Yu SH, Lin JT, et al
    The occurrence of hepatocellular carcinoma in different risk stratifications of clinically non-cirrhotic non-alcoholic fatty liver disease.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30784.
    PubMed     Text format     Abstract available


    April 2017
  26. ZHANG R, Real CI, Liu C, Baba HA, et al
    Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro.
    Int J Cancer. 2017 Apr 17. doi: 10.1002/ijc.30742.
    PubMed     Text format     Abstract available


  27. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    PubMed     Text format     Abstract available


  28. KE Y, Bao T, Zhou Q, Wang Y, et al
    Discs large homolog 5 decreases formation and function of invadopodia in human hepatocellular carcinoma via Girdin and Tks5: Dlg5 regulates HCC invadopodia.
    Int J Cancer. 2017 Apr 8. doi: 10.1002/ijc.30730.
    PubMed     Text format     Abstract available


    March 2017
  29. ZHU M, Li W, Lu Y, Dong X, et al
    HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.
    Int J Cancer. 2017;140:1346-1355.
    PubMed     Text format     Abstract available


  30. WANG W, Lie P, Guo M, He J, et al
    Risk of hepatotoxicity in cancer patients Treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data.
    Int J Cancer. 2017 Mar 6. doi: 10.1002/ijc.30678.
    PubMed     Text format     Abstract available


  31. MA X, Yang Y, Li HL, Zheng W, et al
    Dietary trace element intake and liver cancer risk: Results from two population-based cohorts in China.
    Int J Cancer. 2017;140:1050-1059.
    PubMed     Text format     Abstract available


    February 2017
  32. ZHANG D, Zhao L, Shen Q, Lv Q, et al
    Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30656.
    PubMed     Text format     Abstract available


  33. LI CH, Yen CH, Chen YF, Lee KJ, et al
    Characterization of the GNMT-HectH9-PREX2 Tripartite Relationship in the Pathogenesis of Hepatocellular Carcinoma.
    Int J Cancer. 2017 Feb 16. doi: 10.1002/ijc.30652.
    PubMed     Text format     Abstract available


  34. XU J, Lin H, Li G, Sun Y, et al
    Sorafenib with ASC-J9(R) synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.
    Int J Cancer. 2017;140:705-717.
    PubMed     Text format     Abstract available


    January 2017
  35. WANG W, Bai W, Wang E, Zhao Y, et al
    mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Int J Cancer. 2017;140:390-399.
    PubMed     Text format     Abstract available


    December 2016
  36. YANG X, Wu L, Lin J, Wang A, et al
    Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue.
    Int J Cancer. 2016 Dec 10. doi: 10.1002/ijc.30547.
    PubMed     Text format     Abstract available


  37. WU SM, Lin SL, Lee KY, Chuang HC, et al
    Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30559.
    PubMed     Text format     Abstract available


    November 2016
  38. MOHAMED NK, Hamad MA, Hafez MZ, Wooley KL, et al
    Nanomedicine in Management of Hepatocellular Carcinoma: Challenges and Opportunities.
    Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30517.
    PubMed     Text format     Abstract available


  39. MANTHRAVADI S, Paleti S, Pandya P
    Impact of sustained viral response post curative therapy of hepatitis C-related hepatocellular carcinoma: A systematic review and meta-analysis.
    Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30521.
    PubMed     Text format     Abstract available


  40. KIM G, Jang SY, Han E, Lee YH, et al
    Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
    Int J Cancer. 2016 Nov 7. doi: 10.1002/ijc.30506.
    PubMed     Text format     Abstract available


    August 2016
  41. ZHAO Y, Li H, Bai W, Liu J, et al
    Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Int J Cancer. 2016;139:928-37.
    PubMed     Text format     Abstract available


  42. HASHIMOTO M, Kobayashi T, Tashiro H, Arihiro K, et al
    h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
    Int J Cancer. 2016;139:812-23.
    PubMed     Text format     Abstract available


  43. KI KIM S, Ueda Y, Hatano E, Kakiuchi N, et al
    TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Int J Cancer. 2016 Aug 11. doi: 10.1002/ijc.30379.
    PubMed     Text format     Abstract available


  44. KURAHARA H, Bohl C, Natsugoe S, Nishizono Y, et al
    Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.
    Int J Cancer. 2016;139:628-38.
    PubMed     Text format     Abstract available


    July 2016
  45. JARY M, Lecomte T, Bouche O, Kim S, et al
    Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: A simple biological score.
    Int J Cancer. 2016 Jul 29. doi: 10.1002/ijc.30367.
    PubMed     Text format     Abstract available


    June 2016
  46. XIE G, Wang X, Huang F, Zhao A, et al
    Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis.
    Int J Cancer. 2016 Jun 7. doi: 10.1002/ijc.30219.
    PubMed     Text format     Abstract available


  47. SAHLMAN P, Nissinen M, Pukkala E, Farkkila M, et al
    Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996-2013.
    Int J Cancer. 2016;138:2616-21.
    PubMed     Text format     Abstract available


    May 2016
  48. RAMESH V, Ganesan K
    Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression.
    Int J Cancer. 2016 May 19. doi: 10.1002/ijc.30195.
    PubMed     Text format     Abstract available


    April 2016
  49. AIZAWA K, Liu C, Tang S, Veeramachaneni S, et al
    Tobacco carcinogen (NNK) induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation.
    Int J Cancer. 2016 Apr 26. doi: 10.1002/ijc.30161.
    PubMed     Text format     Abstract available


  50. WANG C, Zhang Y, Guo K, Wang N, et al
    Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential.
    Int J Cancer. 2016;138:1824-34.
    PubMed     Text format     Abstract available


  51. EEFSEN RL, Engelholm L, Willemoe GL, Van den Eynden GG, et al
    Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
    Int J Cancer. 2016;138:1777-84.
    PubMed     Text format     Abstract available


  52. JU HL, Han KH, Lee JD, Ro SW, et al
    Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy.
    Int J Cancer. 2016;138:1601-8.
    PubMed     Text format     Abstract available


    March 2016
  53. LOES IM, Immervoll H, Sorbye H, Angelsen JH, et al
    Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Int J Cancer. 2016 Mar 16. doi: 10.1002/ijc.30089.
    PubMed     Text format     Abstract available


  54. ZIMMERMANN E, Berentzen TL, Gamborg M, Sorensen TI, et al
    Sex-specific associations between birth weight and adult primary liver cancer in a large cohort of Danish children.
    Int J Cancer. 2016;138:1410-5.
    PubMed     Text format     Abstract available


    January 2016
  55. GHOSH A, Ghosh A, Datta S, Dasgupta D, et al
    Hepatic miR-126 is a Potential Plasma Biomarker for Detection of Hepatitis B Virus Infected Hepatocellular Carcinoma.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29999.
    PubMed     Text format     Abstract available


  56. SUN L, Hu S, Yu L, Guo C, et al
    Serum Haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29993.
    PubMed     Text format     Abstract available


    December 2015
  57. MCGLYNN KA, Hagberg K, Chen J, Braunlin M, et al
    Menopausal hormone therapy use and risk of primary liver cancer in the Clinical Practice Research Datalink.
    Int J Cancer. 2015 Dec 13. doi: 10.1002/ijc.29960.
    PubMed     Text format     Abstract available


    September 2015
  58. TAKEUCHI S, Fukuda K, Arai S, Nanjo S, et al
    Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.
    Int J Cancer. 2015 Sep 17. doi: 10.1002/ijc.29858.
    PubMed     Text format     Abstract available


    August 2015
  59. WONG MC, Ching JY, Chan VC, Lam TY, et al
    Screening Strategies for Colorectal Cancer among Patients with Non-Alcoholic Fatty Liver Disease and Family History.
    Int J Cancer. 2015 Aug 20. doi: 10.1002/ijc.29809.
    PubMed     Text format     Abstract available


  60. CORREA D, Somoza RA, Lin P, Schiemann WP, et al
    Mesenchymal Stem Cells regulate Melanoma Cancer Cells extravasation to bone and liver at their perivascular niche.
    Int J Cancer. 2015 Aug 1. doi: 10.1002/ijc.29709.
    PubMed     Text format     Abstract available


    May 2015
  61. HLEYHEL M, Belot A, Bouvier AM, Tattevin P, et al
    Trends in survival after cancer diagnosis among HIV-Infected Individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 Cohort.
    Int J Cancer. 2015 May 14. doi: 10.1002/ijc.29603.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: